ABT vs NXT · P/E 25, rev $44.33B vs P/E 32, rev $3.56B
Abbott Laboratories (ABT) versus Nextracker Inc. Class A Common Stock (NXT) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Nextracker Inc. Class A Common Stock (NXT) is a solar company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported NXT revenue for 2026-03-31 was $3.56B. Net income was $585.9M. Revenue was up 20.3% from 2025-03-31 to 2026-03-31. NXT currently screens at market cap $18.77B and trailing P/E 32.1.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. NXT currently screens at market cap $18.77B and trailing P/E 32.1.
Not investment advice. Open the ABT and NXT stock pages for the full models.
Not investment advice.